A study of DR-01 in Subjects with Alopecia areata and Vitiligo
The purpose of this study is to explore whether an investigational drug can improve results for people with alopecia areata by
destroying the cells that cause their autoimmune disease.
You may be eligible to participate if you meet the following eligibility criteria:
Have been diagnosed with Alopecia Areata between 6 months and 10 years
ago.
Agree to not use adhesive wigs (other than banded perimeter wigs) during
the study
Aged 18 years and older
The trial will consist of a screening period of up to 28 days and, if you are eligible to participate in the study, you will then receive up to 24 weeks (6 months) of treatment, followed by an additional 24 weeks (6 months) of followup
visits.
Participants who successfully complete dosing may receive additional treatment through an extension study.
You will be reimbursed for your time and travel, while supporting medical research
Cornerstone Dermatology
346 Old Cleveland Rd, Coorparoo
QLD 4151
Ph:07 3397 3200
Email: margaretjanders@gmail.com
The Skin Hospital
121 Crown St, Darlinghurst NSW 2010
Email:clinicaltrials@skinhospital.ed
u.au
Ph: 04684 19222
Novatrials
Email: info@novatrials.com.au
Phone: +61 2 4089 3744
Suite 301/99 Pacific Hwy,
Dermatology Institute of Victoria
8-10 Howitt Street, South Yarra VIC
3141
Phone: (03) 9826 4966
Email: clinicaltrials@div.net.au
Fremantle Dermatology
229 High St, Fremantle WA 6160
Phone: (08) 9336 7304
Email:
toni@fremantledermatology.com.au
